About ABL Bio
ABL Bio is a publicly listed company based in Seongnam-si (South Korea) founded in 2016. ABL Bio is engaged in developing biopharmaceuticals for critical diseases. It operates on a HealthTech model. ABL Bio has raised $65 million across 2 funding rounds from investors including DSC Investment, Hana Financial Group and DS Asset. The company has 104 employees. Its website ablbio.com draws about 29 thousand monthly visits. ABL Bio offers products and services including ABL301, ABL503, and ABL111. Its focus areas include Biotechnology and Biopharmaceuticals.
Company details
ABL Bio is focused on the development of innovative biopharmaceuticals targeting challenging diseases such as cancer and neurodegenerative brain disorders. The company is recognized for its dual-antibody platforms, which are utilized in immuno-oncology therapies, neurodegenerative disease treatments, and antibody-drug conjugates (ADCs). Solutions are developed to address low response rates in cancer treatments, enhance brain delivery for neurological therapies, and improve therapeutic indices for rare blood cancers. The sectors served include healthcare and biotechnology, with a strong emphasis on research and clinical advancements.
- Headquarters Seongnam-si, South Korea
- Employees 104
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website ablbio.com
- Social LinkedIn X
- Legal Name Abl Bio, Inc.
- Annual Revenue$54.94 M (USD)137.55as on Dec 31, 2025
- Net Profit-$26.18 M (USD)31.92as on Dec 31, 2025
- EBITDA-$25.58 M (USD)35.15as on Dec 31, 2025
- Total Equity Funding$65M (USD)
in 2 rounds
- Latest Funding Round$65M (USD), Series C
Jun 2018
- InvestorsDSC Investment
& 3 more
- Employee Count104
Associated legal entities of ABL Bio
ABL Bio operates through Abl Bio-Technologies Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Abl Bio-Technologies Limited Listed CIN L52599TN1992PLC022340 | Active | 16 Mar 1992 | Chennai, Tamil Nadu | 3 | View details |
Products & Services of ABL Bio
ABL Bio offers a comprehensive portfolio of products and services, including ABL301, ABL503, and ABL111.
Developed as a treatment for neurodegenerative brain diseases.
Designed as an immuno-oncology therapy for cancer treatment.
Created for gastric cancer as a primary treatment.
Funding Insights of ABL Bio
ABL Bio has successfully raised a total of $65M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $65 million completed in June 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $65M
- Total Rounds 2
- Last Round Series C — $65M
- Investors Count 4
All 2 funding rounds of ABL Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
4 investors in total: 4 institutional.
Investors in ABL Bio
ABL Bio has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include DSC Investment, Hana Financial Group and DS Asset.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage venture capital is invested primarily in South Korean startups. | 2012 | dscinvestment.com | Seoul, South Korea | |
DS Asset is engaged in asset management and investment services. | dsasset.com | Seoul, South Korea | ||
| quad-im.com | ||||
Financial management services are provided to individuals and corporates. | 1971 | hanafn.com | Seoul, South Korea |
Investor details for ABL Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Abl Bio-Technologies Limited (ABL Bio)
Abl Bio-Technologies Limited is the primary company behind ABL Bio. The board of Abl Bio-Technologies Limited currently have 3 directors; the longest-serving is Kollenmareth Oomman Isaac, appointed in 1992. 4 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Kollenmareth Oomman Isaac DIN 01421392 | Managing Director | 16 Mar 1992 | 34 yrs 7 mo | Abl Bio-Technologies Limited |
| Subramanian Gopalakrishnan DIN 00064138 | Director | 30 Oct 2003 | 23 yrs | Abl Bio-Technologies Limited |
| Sankaran Nampoothiri Velliyod Madhavan DIN 01485826 | Director | 13 Dec 2008 | 17 yrs 10 mo | Abl Bio-Technologies Limited |
People of ABL Bio
4 people are tracked at ABL Bio (4 in leadership); the tracked headcount is 104.
| Name | Role | Group |
|---|---|---|
Sang Hoon Lee | CEO/Founder | Leadership |
Jonghwa Won | Head, Translational Research & Early Development | Leadership |
Weon-Kyoo You | R&d Head/executive Vice President | Leadership |
Yongsun Kwon | Director Of Business Operations | Leadership |
Complete people profiles for ABL Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of ABL Bio
ABL Bio is a publicly listed company on the KRX with ticker symbol 298380 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Dec 2018
- Listed onKRX: 298380
- Listed entityABL Bio, Inc.
- Exchange sectorHealth technology
- ISINKR7298380007
- Share price43,100.00 KRW (-0.92% on the day) · 2026-10-14
- Market capitalisation2,435,454,723,358.00 KRW
- EPS (diluted, trailing year)-1,429.42 KRW
- Volume (last session)243,386
Financials of ABL Bio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 79.35B KRW | -37.81B KRW | -36.94B KRW |
| 2024 | 33.40B KRW | -55.53B KRW | -56.97B KRW |
| 2023 | 65.55B KRW | -2.65B KRW | -27.3M KRW |
| 2022 | 67.30B KRW | 3.21B KRW | 3.23B KRW |
| 2021 | 5.33B KRW | -43.56B KRW | -49.03B KRW |
Balance sheet, profit and loss, cash flow and ratios of Abl Bio-Technologies Limited are on its company page.
Detailed financial statements for ABL Bio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of ABL Bio
4 dated milestones of ABL Bio across 2 years, from founding to its latest funding, stage changes and deals.
- Founded ABL Bio is founded.
- Funding First funding round.
- Funding Latest funding round, Series C, of $65.0M.
- IPO Lists on the stock exchange (IPO).
Web traffic of ABL Bio
The website of ABL Bio (ablbio.com) receives about 29.1K visits a month and ranks #1,001,197 among all websites worldwide, #1,227 in Biotechnology and Pharmaceuticals.
- Monthly visits29.1K
▲ 3.4% vs previous month
- Unique visitors12.6K
per month
- Global rank#1,001,197
among all websites
- Category rank#1,227
Health · Biotechnology and Pharmaceuticals
- Bounce rate50%
- Pages per visit2.1
- Average visit14 sec
- DevicesDesktop 32% · Mobile 68%
Websites whose visitors overlap most with ABL Bio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| medicopharma.co.kr | 100% | #596,014 | View details | ||
thebionews.net | thebionews.net | 85% | #353,035 | – | |
| hitnews.co.kr | 77% | #146,502 | View details | ||
| pharmnews.com | 68% | #274,610 | View details | ||
| healthinnews.co.kr | 68% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for ABL Bio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Abl Bio
Complete news archive for ABL Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ABL Bio
ABL Bio was founded in 2016.
ABL Bio is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.
ABL Bio is a funded company, having raised a total of $65M across 2 funding rounds to date.
ABL Bio has 104 employees.
Annual revenue of ABL Bio is $54.94M as on Dec 31, 2025.
ABL Bio is focused on the development of innovative biopharmaceuticals targeting challenging diseases such as cancer and neurodegenerative brain disorders. The company is recognized for its dual-antibody platforms, which are utilized in immuno-oncology therapies, neurodegenerative disease treatments, and antibody-drug conjugates (ADCs). Solutions are developed to address low response rates in cancer treatments, enhance brain delivery for neurological therapies, and improve therapeutic indices for rare blood cancers. The sectors served include healthcare and biotechnology, with a strong emphasis on research and clinical advancements.
ABL Bio offers ABL301, ABL503, and ABL111.
Yes, ABL Bio is publicly traded on KRX under the ticker symbol 298380.
ABL Bio has 4 investors. Key investors include DSC Investment, Hana Financial Group, DS Asset, and QUAD.
ABL Bio operates through Abl Bio-Technologies Limited.
The legal entities of ABL Bio currently have 3 directors, including Subramanian Gopalakrishnan, Kollenmareth Oomman Isaac, Sankaran Nampoothiri Velliyod Madhavan.